Drug Information

Drug General Information
Drug ID
D03KKR
Former ID
DNC000640
Drug Name
Fasudil
Drug Type
Small molecular drug
Indication Discovery agent Phase 3 [468243], [522059]
Structure
Download
2D MOL

3D MOL
Formula
C14H17N3O2S
InChI
InChI=1S/C14H17N3O2S/c18-20(19,17-9-2-6-15-8-10-17)14-4-1-3-12-11-16-7-5-13(12)14/h1,3-5,7,11,15H,2,6,8-10H2
InChIKey
NGOGFTYYXHNFQH-UHFFFAOYSA-N
CAS Number
CAS 103745-39-7
PubChem Compound ID
3547
PubChem Substance ID
645246, 830160, 841200, 7411211, 7888736, 8152246, 11113364, 11121731, 11122211, 11362865, 11365427, 11367989, 11370941, 11370942, 11373590, 11376151, 14849184, 26751605, 26751606, 29222678, 46392968, 46394056, 46394198, 46514392, 47810568, 47959546, 48034909, 48110269, 48184808, 49961274, 50100814, 50871527, 53790340, 57321867, 81062559, 85787246, 85787262, 91614085, 92251456, 92308789, 92310082, 92708292, 93577882, 96024636, 99300994, 99302514, 99444633, 103064513, 103083244, 103210437
SuperDrug ATC ID
C04AX32
SuperDrug CAS ID
cas=103745397
Target and Pathway
Target(s) Rho-associated protein kinase 1 Target Info Inhibitor [535190]
KEGG Pathway cGMP-PKG signaling pathway
cAMP signaling pathway
Chemokine signaling pathway
Sphingolipid signaling pathway
Vascular smooth muscle contraction
TGF-beta signaling pathway
Axon guidance
Focal adhesion
Platelet activation
Leukocyte transendothelial migration
Regulation of actin cytoskeleton
Oxytocin signaling pathway
Pathogenic Escherichia coli infection
Shigellosis
Salmonella infection
Pathways in cancer
Proteoglycans in cancer
MicroRNAs in cancer
PANTHER Pathway Cytoskeletal regulation by Rho GTPase
Inflammation mediated by chemokine and cytokine signaling pathway
CCKR signaling map ST
Pathway Interaction Database Signaling events mediated by PRL
RhoA signaling pathway
Noncanonical Wnt signaling pathway
EPHB forward signaling
Thromboxane A2 receptor signaling
PAR4-mediated thrombin signaling events
amb2 Integrin signaling
Integrins in angiogenesis
EPHA forward signaling
Stabilization and expansion of the E-cadherin adherens junction
Signaling events mediated by VEGFR1 and VEGFR2
PAR1-mediated thrombin signaling events
N-cadherin signaling events
Reactome Apoptotic cleavage of cellular proteins
EPHB-mediated forward signaling
EPHA-mediated growth cone collapse
G alpha (12/13) signalling events
Sema4D induced cell migration and growth-cone collapse
VEGFA-VEGFR2 Pathway
RHO GTPases Activate ROCKs
WikiPathways G13 Signaling Pathway
Regulation of Actin Cytoskeleton
EGF/EGFR Signaling Pathway
TGF beta Signaling Pathway
Focal Adhesion
JAK/STAT
AGE/RAGE pathway
Pathogenic Escherichia coli infection
Regulation of Microtubule Cytoskeleton
Leptin signaling pathway
Semaphorin interactions
Integrin-mediated Cell Adhesion
GPCR downstream signaling
Apoptotic execution phase
MicroRNAs in cardiomyocyte hypertrophy
Androgen receptor signaling pathway
References
Ref 468243(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5181).
Ref 522059ClinicalTrials.gov (NCT00498615) A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon. U.S. National Institutes of Health.
Ref 535190Long-term inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo. Cardiovasc Res. 2001 Jul;51(1):169-77.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.